NGFR and hypopharynx cancer: Morita and colleagues introduced CD271 as a CSC biomarker of hypopharyngeal cancer and developed an anti‐CD271 mAb, targeting CD271‐positive cells in xenograft models, eventuated in the decrease of CD271‐expressing CSCs through ADCC mechanism.158